ArticleCell reports. Medicine2023

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.

Roeland Lameris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.